
Onconetix, Inc. is a commercial stage biotechnology company. It is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has Entadfi, a Food and Drug Administration approved, oral therapeutic for ... Onconetix, Inc. is a commercial stage biotechnology company. It is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has Entadfi, a Food and Drug Administration approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5¿-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a next generation protein-based blood test that can be done with the same sample as a patient's regular PSA test. Proteomedix is seeking to develop diagnostic, prognostic, and predictive tools to enable cancer management at all stages of disease progression. 詳細を表示
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0166 | -18.6307519641 | 0.0891 | 0.1496 | 0.065 | 22081779 | 0.10388789 | CS |
4 | -0.1475 | -67.0454545455 | 0.22 | 0.245 | 0.065 | 9169255 | 0.11590135 | CS |
12 | -0.5623 | -88.5790800252 | 0.6348 | 1.04 | 0.065 | 7153372 | 0.39390337 | CS |
26 | -4.1875 | -98.2981220657 | 4.26 | 6.5 | 0.065 | 5954515 | 0.51621074 | CS |
52 | -6.0075 | -98.8075657895 | 6.08 | 21.4 | 0.065 | 6699305 | 4.86266363 | CS |
156 | -7.9275 | -99.09375 | 8 | 21.4 | 0.065 | 6043682 | 5.76617534 | CS |
260 | -7.9275 | -99.09375 | 8 | 21.4 | 0.065 | 6043682 | 5.76617534 | CS |
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約